Pyridine-Sulfonamide Sigma Ligand Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for highly selective and effective ligands that target sigma-2 receptors over sigma-1 receptors, as current ligands often lack selectivity and have poor pharmaceutical properties, making it challenging to develop effective treatments for disorders related to these receptors.
Innovation Solution
Development of novel pyridine-sulfonamide derivatives with a specific chemical formula that exhibit selective affinity for sigma-1 and sigma-2 receptors, which can be used in pharmaceutical compositions for treating pain and CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ligands are used to target sigma receptors, then they can bind to sigma-1 and sigma-2 receptors, but they lack selectivity between the two receptor subtypes and have poor pharmaceutical properties
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions of the sulfonamide core structure. The pyridine ring is positioned at the sulfonamide nitrogen, while specific substituents are placed at positions 2, 4, and 6 of the pyridine ring to create localized interactions with sigma-2 receptor that distinguish it from sigma-1 receptor binding.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituents at multiple positions of the pyridine-sulfonamide structure. Different halogen atoms, alkyl groups, and heterocyclic substituents are introduced to optimize the balance between affinity for both sigma receptors and selectivity for sigma-2, thereby improving pharmaceutical properties.
2Manufacturing precision
If highly selective sigma-2 ligands are developed, then selectivity over sigma-1 receptors improves, but pharmaceutical properties such as bioavailability and metabolic stability remain challenging
Solution Approach 1:
The patent optimizes pharmaceutical properties by carefully selecting substituents that balance selectivity with drug-like characteristics. For example, fluorine atoms and small alkyl groups are chosen to maintain molecular size and lipophilicity within acceptable ranges for oral bioavailability, while still providing the necessary steric and electronic features for sigma-2 selectivity.
Solution Approach 2:
The patent creates composite molecular structures by combining the pyridine-sulfonamide core with various heterocyclic and aromatic substituents. This composite approach allows the molecule to simultaneously engage multiple interaction types (hydrogen bonding, pi-stacking, hydrophobic interactions) that enhance both selectivity and pharmacokinetic properties.
Data Source
AI summary
The present invention relates to new pyridine-sulfonamide derivatives of formula (I′) as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.